Literature DB >> 22561837

Therapies for allergic inflammation: refining strategies to induce tolerance.

Cezmi A Akdis1.   

Abstract

Current therapies for asthma and allergy are relatively safe and effective at controlling symptoms but do not change the chronic course of disease. There is no established method to prevent asthma and allergy, and major unmet needs in this area include the better control of the severe forms of these diseases and the developments of curative therapies. Two major therapeutic strategies for asthma and allergy are currently being developed, and I here discuss the advances and challenges for future therapeutic development in these two areas. The first approach, allergen-specific immunotherapy, aims to induce specific immune tolerance and has a long-term disease-modifying effect. The second approach is the use of biological immune response modifiers to decrease pathological immune responses. Combination strategies using both of these approaches may also provide a route for addressing the unmet clinical needs in allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561837     DOI: 10.1038/nm.2754

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  147 in total

1.  Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.

Authors:  Calman Prussin; Daniel T Griffith; Kevin M Boesel; Henry Lin; Barbara Foster; Thomas B Casale
Journal:  J Allergy Clin Immunol       Date:  2003-12       Impact factor: 10.793

Review 2.  TNFalpha blockade in human diseases: an overview of efficacy and safety.

Authors:  Jan Lin; David Ziring; Sheetal Desai; Sungjin Kim; Maida Wong; Yael Korin; Jonathan Braun; Elaine Reed; David Gjertson; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-04       Impact factor: 3.969

3.  Circulating Foxp3+CD4+ cell numbers in atopic patients and healthy control subjects.

Authors:  Kanami Orihara; Masami Narita; Takashi Tobe; Akira Akasawa; Yukihiro Ohya; Kenji Matsumoto; Hirohisa Saito
Journal:  J Allergy Clin Immunol       Date:  2007-07-12       Impact factor: 10.793

Review 4.  Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.

Authors:  Gustavo J Rodrigo; Hugo Neffen; José A Castro-Rodriguez
Journal:  Chest       Date:  2010-08-05       Impact factor: 9.410

5.  Treatment of cat allergy with T-cell reactive peptides.

Authors:  P S Norman; J L Ohman; A A Long; P S Creticos; M A Gefter; Z Shaked; R A Wood; P A Eggleston; K B Hafner; P Rao; L M Lichtenstein; N H Jones; C F Nicodemus
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

6.  Evidence that vitamin D(3) promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice.

Authors:  Lisa Biggs; Chunping Yu; Boris Fedoric; Angel F Lopez; Stephen J Galli; Michele A Grimbaldeston
Journal:  J Exp Med       Date:  2010-03-01       Impact factor: 14.307

7.  Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities.

Authors:  Erika A Rickel; Lori A Siegel; Bo-Rin Park Yoon; James B Rottman; David G Kugler; David A Swart; Penny M Anders; Joel E Tocker; Michael R Comeau; Alison L Budelsky
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Authors:  Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606

9.  Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy.

Authors:  Peter Rullan; Jenny Murase
Journal:  J Drugs Dermatol       Date:  2009-09       Impact factor: 2.114

10.  Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells.

Authors:  M Pierkes; I Bellinghausen; T Hultsch; G Metz; J Knop; J Saloga
Journal:  J Allergy Clin Immunol       Date:  1999-02       Impact factor: 10.793

View more
  85 in total

1.  Regulatory T cells and regulation of allergic airway disease.

Authors:  Helen Martin; Christian Taube
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

Review 2.  Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes.

Authors:  Andrew L Kau; Phillip E Korenblat
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-12

3.  A computational model of unresolved allergic inflammation in chronic asthma.

Authors:  Joshua J Pothen; Matthew E Poynter; Jason H T Bates
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-19       Impact factor: 5.464

4.  Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs.

Authors:  Cezmi A Akdis; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 5.  MicroRNAs in allergy and asthma.

Authors:  Ana Rebane; Cezmi A Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2014-04       Impact factor: 4.806

6.  Using preoperative unsupervised cluster analysis of chronic rhinosinusitis to inform patient decision and endoscopic sinus surgery outcome.

Authors:  Choaib Adnane; Taoufik Adouly; Amine Khallouk; Sami Rouadi; Redallah Abada; Mohamed Roubal; Mohamed Mahtar
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-24       Impact factor: 2.503

7.  Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.

Authors:  Takumi Kiwamoto; Toshihiko Katoh; Michael Tiemeyer; Bruce S Bochner; Christopher M Evans; William J Janssen; Mary E Brummet; Sherry A Hudson; Zhou Zhu
Journal:  J Allergy Clin Immunol       Date:  2014-12-12       Impact factor: 10.793

8.  Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

Authors:  Cezmi A Akdis; Claus Bachert; Cemal Cingi; Mark S Dykewicz; Peter W Hellings; Robert M Naclerio; Robert P Schleimer; Dennis Ledford
Journal:  J Allergy Clin Immunol       Date:  2013-04-12       Impact factor: 10.793

9.  The inflammatory twitch as a general strategy for controlling the host response.

Authors:  Joshua J Pothen; Matthew E Poynter; Jason H T Bates
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

Review 10.  Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways.

Authors:  Norbert Meyer; Cezmi A Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.